Molecular Imaging 2017

Assessing Therapy: Cervical Cancer

 n=60  IB 2

 N=80  IB2 through IVA  Combination of pre RT tumour volume & MRI

-IVB/recurrent



Tumor regression rate (fast vs. slow) at mid-RT (45–50 Gy) best outcome prediction for local control (84% vs. 22%, p < 0.0001) & disease-free survival (63% vs. 20%, p = 0.0005)

regression ratio 4-5 weeks post CRT best predictor of local control: 89% sensitivity, 87% specificity, 88% accuracy for LR

Mayr et al. Int J Radiat Oncol Biol Phys 2002;52(1):14-22

Wang et al. Cancer 2010;116(21) 5093-101.